Multiple Endocrine Neoplasia Type 2a: Clinical Trials

15 trials for Multiple Endocrine Neoplasia Type 2a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 4 recruiting, 1 unknown, 1 withdrawn. 7 Phase 1, 3 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 17Completed 5, Recruiting 1, Withdrawn 1
Phase 23Completed 3
Phase 32Completed 2

Follow Multiple Endocrine Neoplasia Type 2a: new trials by email Literature Review of Multiple Endocrine Neoplasia Type 2a trials Research Report on Multiple Endocrine Neoplasia Type 2a

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
RecruitingUniversidad Nacional Autonoma de Mexico7502022-08-032024-07-26
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
BNT116, Cemiplimab, Docetaxel - Non-Small Cell Lung Cancer
Phase 1RecruitingBioNTech SE3202022-06-172026-07-22
Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer
Liquid biopsy - Lung Cancer
UnknownUniversity of Milano Bicocca202021-12-122023-10-13
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
BOS172738 - Advanced Nonhaematologic Malignancies
Phase 1CompletedBoston Pharmaceuticals1172018-12-122023-10-30
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Phase 1WithdrawnVanderbilt-Ingram Cancer Center2017-12-012017-09-28
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Alectinib, Crizotinib - Neoplasms
Phase 3CompletedHoffmann-La Roche502017-07-052026-10-09
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
GSK3352589, Matching Placebo - Irritable Bowel Syndrome
Phase 1CompletedGlaxoSmithKline682017-05-172019-08-09
Familial Investigations of Childhood Cancer Predisposition
Acute Leukemia, Adenomatous Polyposis
RecruitingSt. Jude Children's Research Hospital15002017-04-062026-06-17
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2CompletedHoffmann-La Roche5902017-03-172025-05-31
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GSK3179106, Placebo - Irritable Bowel Syndrome
Phase 1CompletedGlaxoSmithKline162015-11-262017-05-08
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
CompletedNational Cancer Institute (NCI)1502010-07-052018-04-05
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingSanford Health200002010-07-012026-10-28
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Vandetanib - Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)172007-07-202020-12-22
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Sorafenib Tosylate - Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)212006-11-032024-02-06
Cinacalcet to Treat Familial Primary Hyperparathyroidism
Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism
Phase 3CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)252006-05-092017-07-02

Narrower conditions

Carcinoma, Medullary (8)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Multiple Endocrine Neoplasia Type 1 (4)  ·  Multiple Endocrine Neoplasia Type 2b (4)  ·  Multiple Endocrine Neoplasia (3)  ·  Neuroendocrine Tumors (3)  ·  Pheochromocytoma (3)  ·  Carney Complex (2)  ·  Colorectal Neoplasms, Hereditary Nonpolyposis (2)  ·  Hamartoma Syndrome, Multiple (2)  ·  Insulinoma (2)  ·  Irritable Bowel Syndrome (2)  ·  Li-Fraumeni Syndrome (2)  ·  Lung Neoplasms (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15)  ·  Genetic Diseases, Inborn (15)  ·  Neoplasms, Multiple Primary (15)  ·  Neoplastic Syndromes, Hereditary (15)  ·  Endocrine Gland Neoplasms (14)  ·  Endocrine System Diseases (14)  ·  Neoplasms by Site (14)  ·  Neoplasms (13)  ·  Multiple Endocrine Neoplasia (12)  ·  Neoplasms by Histologic Type (9)  ·  Adenocarcinoma (8)  ·  Carcinoma (8)  ·  Neoplasms, Ductal, Lobular, and Medullary (8)  ·  Neoplasms, Germ Cell and Embryonal (8)  ·  Neoplasms, Glandular and Epithelial (8)

Interventions

Antibodies, Bispecific (1)  ·  Capecitabine (1)  ·  Carboplatin (1)  ·  Crizotinib (1)  ·  Docetaxel (1)  ·  GSK3352589 (1)  ·  Liquid Biopsy (1)  ·  Paclitaxel (1)  ·  Sorafenib (1)  ·  Temozolomide (1)  ·  Vascular Endothelial Growth Factor A (1)  ·  alectinib (1)  ·  cemiplimab (1)  ·  osimertinib (1)  ·  pralsetinib (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  GlaxoSmithKline (2)  ·  Hoffmann-La Roche (2)  ·  BioNTech SE (1)  ·  Boston Pharmaceuticals (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Sanford Health (1)  ·  St. Jude Children's Research Hospital (1)  ·  Universidad Nacional Autonoma de Mexico (1)  ·  University of Milano Bicocca (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (10)  ·  Spain (4)  ·  Australia (3)  ·  France (3)  ·  Hong Kong (3)  ·  Italy (3)  ·  South Korea (3)  ·  Belgium (2)  ·  Germany (2)  ·  Poland (2)  ·  Taiwan (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  China (1)  ·  Hungary (1)

Top investigators

Antonio T Fojo, M.D. (1)  ·  Bhavana Konda (1)  ·  Brigitte C Widemann, M.D. (1)  ·  Diego Cortinovis, MD (1)  ·  Jordan Berlin, M.D. (1)  ·  Kim E. Nichols, MD (1)  ·  Luca Mologni, PhD (1)

Results publications

PMID 23766359, PMID 24617713, PMID 25972901, PMID 29187393, PMID 30277655, PMID 33606922, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723

NIH funding

2016 (1), 2017 (1), 2018 (1), 2023 (1), N01CM00070 (1), N01CM62207 (1), P30CA016058 (1)